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The present study investigates the protective efficacy of stem bromelain against lead-induced toxicity in 
male Wistar rats. There were six experimental groups; Group I was negative control, Group II was admin-
istered only 20 mg/kg of stem bromelain. Group III and V were orally exposed to 30 mg/kg/day and 
60 mg/kg/day of lead acetate, respectively. Group IV and Group VI were exposed to both low and high 
dose of lead acetate, respectively, and treated with 20 mg/kg stem bromelain. The experimental period 
was 21 days. The end points evaluated were, lead accumulation in kidney, liver and spleen, alanine ami-
notransferase (ALT) and aspartate aminotransferase (AST) activity, serum malonaldehyde (MDA) cho-
lesterol and triglycerides levels. Co-administration of stem bromelain with lead markedly reduced the 
lead accumulation in the kidney and spleen. The treatment of stem bromelain also reduced the serum 
MDA levels in the group exposed to lower dose of lead and serum triglyceride level in the group exposed 
to higher dose of lead. The lead-induced modulated levels of serum ALT and AST were also alleviated by 
bromelain treatment. Our key findings suggest a chelating potential of stem bromelain for combating lead 
toxicity and oxidative stress. Bromelain represents a novel approach to the treatment of metal toxicity and 
metabolic disorders with a limited therapeutic window.
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INTRODUCTION
Lead (Pb) is a toxic heavy metal and the most important exposure route is through the 
ingestion of Pb-polluted food or soil [6]. Pb accumulates in many body organs, pri-
marily in the liver, kidneys and bone thus causing cellular damage [24]. Recently, it 
has been suggested that certain physiological disorders attributed to this heavy metal 
are directly or indirectly related to the generation of reactive oxygen species (ROS) 
that leads to a condition termed as oxidative stress [2, 14, 20]. Plant extracts and 
phytoconstituents have been found to be effective as radical scavengers and inhibitors 
of lipid peroxidation [10]. It has been hypothesized that usage of an antioxidant agent 
in the presence of a chelator would increase the efficacy of intoxication treatment 
with lead [12]. Currently there has been an increased interest globally to identify 
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compounds from plant sources which are pharmacologically potent and have low or 
no side effects for use in protective medicine and the food industry.
The medicinal qualities of pineapple plant, Ananas comosus have been recognized 
in several native cultures [11] and are attributed to bromelain (EC 3.4.22.32), which 
is a crude extract from pineapple stem or fruit. Bromelain contains, among other 
compounds, various closely related thiol endopeptidases, exhibiting various fibri-
nolytic, antithrombotic, and anti-inﬂammatory activities in vitro and in vivo. 
Bromelain concentration is high in pineapple stem, thus necessitating its extraction, 
as the stem is a waste byproduct and thus inexpensive [22]. Bromelain can be 
absorbed in human intestines without degradation and without losing its biological 
activity [7]. Bromelain has a wide range of therapeutic benefits, but the mode of its 
action is not well understood. An extensive review by Pavan et al. [18] suggest that 
bromelain can be an effective potential health supplement to prevent cancer, diabetes, 
and various cardiovascular diseases in the near future.
With the present premise, this study was designed to assess the ameliorative effect 
of stem bromelain on the Pb induced toxicity.
MATERIALS AND METHODS
Chemicals
All chemicals were obtained commercially and were of analytical grade. Lead acetate 
(trihydrate) (Pb(C2H3O2)2 ∙ 3H2O was procured from LOBA Chemie (India). Stem 
bromelain extract as capsules (2400 GDU/g), was procured from iHerb® (United 
States). Commercial kits for the estimation of serum cholesterol and triglycerides 
were procured from Roche (USA). Commercial ELISA kits used for the estimation 
of enzyme activity (alanine aminotransferase, ALT and aspartate aminotransferase, 
AST) were procured from CUSABIO Life Sciences (China).
Experimental design
Forty-five male Wistar rats weighing 150–200 g were procured from the Animal 
House facility at King Saud University, Riyadh in the month of April, 2013. All ani-
mal treatments were performed in accordance with the standards set forth in the 
Guidelines for the Care and Use of Experimental Animals by the Committee for the 
Purpose of Control and Supervision of Experiments on Animals (CPCSEA) and the 
National Institute of Health (NIH) (http://icmr.nic.in/bioethics/final_cpcsea.pdf). The 
study protocol was approved by the Animal Ethics Committee of the Zoology 
Department, College of Science, King Saud University. The animals were acclimated 
to the laboratory conditions for two weeks prior to the experimental period. 
Thereafter, the animals were divided into six groups each comprising seven rats. Rats 
were exposed for three weeks to the following treatments:
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Group I – negative control (administered only normal saline)
Group II – administered only Br 20 mg/kg 
Group III – exposed to only PbAc (lead acetate) 30 mg/kg (positive control)
Group IV – exposed to only PbAc 30 mg/kg + treated with Br 20 mg/kg
Group V – exposed to only PbAc 60 mg/kg (positive control)
Group VI – exposed to PbAc 60 mg/kg + treated with Br 20 mg/kg
 
Bromelain capsules were crushed and ground and administered in normal saline. The 
doses were given daily at 8 am. During the experimental period the rats were fed with 
the laboratory chow. The body weight was recorded on weekly intervals during the 
experimental period. After the experimental period was over blood was drawn by the 
orbital sinus venipuncture from the rats of each experimental group and serum was 
prepared. The serum was prepared by drawing the blood into red stoppered tubes and 
left at room temperature for clotting followed by centrifugation at 3500 rpm for 
15–20 min.The animals were sacrificed and dissected to excise the liver, kidney and 
spleen. The tissues and serum was stored at –80 °C till further analysis. The serum 
was used for the analysis of lipid profile, MDA level and enzymes.
Determination of lead concentration
Samples of kidney, liver, and spleen (0.5 g each) were wet digested with 3.5 ml of 
HNO3 (65%) and 0.5 mL of H2O2 (30%) in a microwave digestor (Milestone, Italy).
The concentration of lead in digested tissue samples was analyzed in an atomic 
absorption spectrophotometer (220 FS Varian, Australia) at wavelength of 228.8 nm 
(detection limit 0.0020 μg/ml) with 4.0 mA current. The final concentrations were 
expressed as μg/g.
Biochemical analysis
Lipid profile
 
Total cholesterol and triglycerides levels in the serum samples were determined using 
commercially available Reﬂotron test strips.
 
 
Determination of serum MDA level
 
MDA levels in serum were determined using the Alliance Waters High performance 
Liquid Chromatography (HPLC) 2695 system and a multi ﬂuorescence detector, 
Model 2475. This system was operated by a Dell Optiplex GX1 computer and 
Empower software. The reversed-phase analytical HPLC column was a ODS 
Hypersil from Thermo Scientific (4.6 mm × 25.0 cm × 5 µm). A guard column, Waters 
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Symmetry TM C18 (4.6 mm × 2 cm, 5 µm particle size) with the same packing mate-
rials was placed in front of the analytical column for protection. The elution was 
carried out at a ﬂow rate of 1.0 mL/min. The column efﬂuent was quantified at an 
excitation and emission wavelengths of 515 and 553 nm, respectively. Run time per 
sample was 4.0 min. Aliquots of 25 µL of serum were mixed thoroughly with 1 mL 
of Thiobarbituric acid (TBA) reagent and 10 µL of 5% Butylated hydroxytoluene 
(BHT) solution, vortexed for 2 minutes and then heated for 60 min in a water bath at 
95 °C. Hereafter, the sample was cooled for 20 minutes and then centrifuged at 
4,000 rpm for 15 min. Supernatants were transferred to a glass vial, and injected a 
5 µL aliquot onto the column. The stock solution of 1,1,3,3 tetraethoxypropane (TEP) 
(10 µmol/mL) was prepared by dissolving 240 µL of 4.176M TEP in 100 mL ethanol 
and stored at 4 °C. The intermediate working standards were prepared by diluting the 
MDA stock solution with water to concentrations of 0.5, 1.0, 2.5, 5.0, 7.5 and 
15 nmol/ml. The MDA levels in the samples were expressed as nmol/ml of serum.
 
 
Determination of alanine aminotransferase (ALT) and 
aspartate aminotransferase (AST) activity
 
Commercial ELISA kits from Cusabio (China) were used to determine the serum ALT 
and AST levels. The serum samples were centrifuged after thawing before the assay 
was performed. All the reagents were prepared and the assays performed in accor-
dance with the manufacturer’s protocol provided with the kit. The optical density was 
determined using a microplate reader set to 450 nm. The AST and ALT activities were 
expressed as units per gram of wet tissue.
Statistical analysis
All presented data are expressed as mean values ± standard error (SE). One-way 
analysis of variance (ANOVA) was performed followed by an unpaired student’s 
t-test to analyze group differences. Numerical data were correlated with SPSS 16.0 
statistical software (Chicago, II, USA). The significance level was set to p ≤ 0.05, 
p ≤ 0.01, p ≤ 0.001.
RESULTS
Lead concentration in tissues
There was no significant difference observed in the Pb concentration in the analyzed 
tissues from the negative control group and the group treated with only bromelain 
(Br). Overall, the effect of bromelain treatment was more marked in the kidneys and 
spleen.
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Kidneys
 
The concentration of Pb in kidneys was invariably significantly higher (p ≥ 0.001) in 
rats from the positive control groups (Pb30 and Pb60) exposed to lead only, in com-
parison to the negative control group. Bromelain administration to lead exposed 
groups (Pb30 + Br and Pb60 + Br) did reduce the Pb concentration significantly 
(p ≥ 0.01) in comparison to the positive controls (Pb30 and Pb60) groups (Fig. 1).
Liver
 
In the liver, the Pb concentration was significantly (p ≥ 0.001) higher only in the 
positive control group with the higher dose of Pb (Pb60) in comparison to the control.
The value observed was also significantly (p ≥ 0.05) higher than that observed in the 
group exposed to a lower dose of Pb (Pb30). Although there was a drop in Pb accu-
mulation in the groups Pb30 + Br and Pb60 + Br on bromelain treatment, the decrease 
was not statistically significant in comparison to the positive control groups (Fig. 2).
 
 
Spleen
 
The concentration of Pb in spleen was invariably significantly higher (p ≥ 0.001) in 
rats from the positive control groups (Pb30 and Pb60) exposed to lead only, in com-
parison to the negative control group. The treatment with bromelain was equally 
effective in lowering the Pb concentration in both Pb30 + Br (p ≥ 0.001) and Pb60 + Br 
(p ≥ 0.01) in comparison to the positive control groups (Fig. 3).
Fig. 1. Effect of stem bromelain treatment on lead concentration in kidney of rats exposed to lead acetate 
(PbAc). Values are expressed as mean ± standard error (n = 4). Same letters indicate significant differ-
ences between groups (p ≥ 0.01, p ≥ 0.001)
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Blood biochemical variables
Serum MDA levels
 
There was no significant difference observed in the serum MDA levels in the negative 
control group and the group exposed to bromelain alone. Exposure to Pb signifi-
cantly (p ≥ 0.001) enhanced the serum MDA levels in both positive control groups 
Fig. 2. Effect of stem bromelain treatment on lead concentration in liver of rats exposed to 30 mg/kg and 
60 mg/kg of lead acetate (PbAc). Values are expressed as mean ± standard error (n = 4). Same letters 
indicate significant differences between groups (p ≥ 0.05, p ≥ 0.001)
Fig. 3. Effect of stem bromelain treatment on lead concentration in spleen of rats exposed to 30 mg/kg 
and 60 mg/kg of lead acetate (PbAc). Values are expressed as mean ± standard error (n = 4). Same letters 
indicate significant differences between groups (p ≥ 0.01, p ≥ 0.001)
Effect of stem bromelain on lead toxicity 155
Acta Biologica Hungarica 66, 2015
(Pb30 and Pb60). Within the group exposed to the lower dose of Pb (30 mg/kg body 
wt/day), treatment with bromelain significantly (p ≥ 0.001) lowered the serum MDA 
levels. However, bromelain treatment was not effective whithin the group exposed to 
the higher dose of Pb (60 mg/kg body wt/day), as there was no significant difference 
observed in the MDA levels between the groups, Pb60 and Pb60 + Br (Fig. 4).
Fig. 4. Effect of stem bromelain treatment serum MDA levels (nmol/ml) of rats exposed to 30 mg/kg and 
60 mg/kg of lead acetate (PbAc). Values are expressed as mean ± standard error (n = 4). Same letters 
indicate significant differences between groups (p ≥ 0.01, p ≥ 0.001)
Fig. 5. Effect of stem bromelain treatment serum triglyceride levels (gm/dl) of rats exposed to 30 mg/kg 
and 60 mg/kg of lead acetate (PbAc). Values are expressed as mean ± standard error (n = 4). Same letters 
indicate significant differences between groups (p ≥ 0.01, p ≥ 0.001)
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Serum triglycerides and cholesterol 
 
There was no significant difference observed in the levels of serum triglycerides and 
cholesterol in the negative control group and the group exposed to bromelain alone 
(Br). Exposure to Pb showed a significant (p ≥ 0.01) increase in the serum triglyceride 
Fig. 6. Effect of stem bromelain treatment serum cholesterol levels (gm/dl) of rats exposed to 30 mg/kg 
and 60 mg/kg of lead acetate (PbAc). Values are expressed as mean ± standard error (n = 4)
Fig. 7. Effect of stem bromelain treatment serum ALT levels (mlU/ml) of rats exposed to 30 mg/kg and 
60 mg/kg of lead acetate (PbAc). Values are expressed as mean ± standard error (n = 4). Same letters 
indicate significant differences between groups (p ≥ 0.01, p ≥ 0.001)
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level only at the higher dose (Pb60) when compared to the negative control. Within 
the high dose groups (Pb60 and Pb60 + Br), treatment with bromelain showed a sig-
nificant (p ≥ 0.01) reduction in the serum triglycerides level. However, there was no 
significant effect of Pb exposure and the bromelain treatment in the groups exposed 
to the lower dose of Pb (30 mg/kg body wt/day) (Fig. 5). Further, during the experi-
mental period there was no significant change in the serum cholesterol levels between 
all experimental groups (Fig. 6).
 
 
Serum alanine aminotransferase (ALT) and aspartate 
aminotransferase(AST) 
 
There was no significant difference observed in the levels of serum ALT and AST in 
the negative control group and the group exposed to bromelain alone (Br). In com-
parison to the negative control group, the groups exposed to Pb (Pb30 and Pb60) 
recorded a significant (p ≥ 0.001) increase in the serum ALT levels. The increase in 
the Pb exposed groups was dose-dependent being significantly (p ≥ 0.001) higher in 
group exposed to the higher dose of lead (Pb60) in comparison to the group exposed 
to lower dose of lead (Pb30). Treatment with bromelain was effective at both doses 
of Pb exposure. A significant (p ≥ 0.01) decrease in the serum ALT level was observed 
in the group, Pb30 + Br in comparison to the Pb30. Similarly, whithin the high dose 
groups (Pb60 and Pb60 + Br), the bromelain treatment significantly (p ≥ 0.001) 
reduced the serum ALT levels (Fig. 7). The pattern of the serum AST level was dif-
Fig. 8. Effect of stem bromelain treatment serum AST levels (mlU/ml) of rats exposed to 30 mg/kg and 
60 mg/kg of lead acetate (PbAc). Values are expressed as mean ± standard error (n = 4). Same letters 
indicate significant differences between groups (p ≥ 0.01, p ≥ 0.001)
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ferent, a significant (p ≥ 0.001) decrease was observed in the untreated lead exposed 
groups (Pb30 and Pb60) in comparison to the control. Treatment with bromelain 
significantly (Pb30 + Br, p ≥ 0.001; Pb60 + Br, p ≥ 0.05) enhanced the serum AST lev-
els and restored it to a level comparable to the control (Fig. 8).
DISCUSSION
Our study did not show any adverse effects of stem bromelain administration on the 
rats during the experimental period, the parameters assessed, lead accumulation in 
kidney, liver and spleen, serum MDA levels, ALT and AST activity, cholesterol and 
triglycerides in group administered only bromelain were comparable to the control. 
Lead exposure at both doses (30 mg/kg and 60 mg/kg) in the rats did increase the 
accumulation of lead in the analyzed tissues being more marked in the kidney as 
reported earlier [13] followed by spleen and liver. The treatment with bromelain did 
cause a significant reduction of Pb accumulation in the kidney and spleen, however, 
in the liver there was no detectable change observed due to bromelain treatment. The 
levels of serum MDA, a biomarker of metal-induced lipid peroxidation, were signifi-
cantly increased in the groups exposed to both low and high doses of Pb in compari-
son to the control group which are consistent with the earlier studies [15, 16]. 
Bromelain effectively reduced the MDA levels in the group exposed to a lower dose 
of lead. Our results on lead bioaccumulation and lipid peroxidation demonstrate a 
moderate ameliorative effect of stem bromelain on lead-induced toxicity in the rats. 
This can be explained on the presence of cysteine, an amino acid with known anti-
oxidant properties. It is also an important precursor in the production of antioxidant 
glutathione, which protects cells from toxins such as free radicals incriminated in 
lead-induced oxidative stress [19]. Thus the cysteine in the bromelain could be a fac-
tor which helped in combating the oxidative stress. Chelation therapy has historically 
been used in attempts to reduce the body burden of toxic metals, including lead in 
highly symptomatic patients with elevated biological markers [5]. The majority of 
proteins and peptides that function in the uptake, distribution, storage or detoxifica-
tion of essential and non-essential metal ions possess one or several metal-binding 
sites. The Cys-X-X-Cys- and -Cys-Cys- motifs of various proteins are well known for 
their heavy metal binding properties [8]. It has long been acknowledged that sulfhy-
dryl-containing compounds have the ability to chelate metals. The sulfur-containing 
amino acids methionine and cysteine, tripeptide glutathione which also contains 
cysteine all contribute to the chelation and excretion of metals from the human body. 
The presence of a highly reactive cysteine in bromelain could have a plausible chelat-
ing effect. Further, our findings on lipid profile and biochemical parameters indicative 
of liver functions reveal a modulatory effect of lead exposure to the rats which was 
restored by the bromelain treatment. Several studies have incriminated lead exposure 
to lipid abnormalities and risk of atherosclerosis [17]. However, effect of Pb exposure 
on the lipid profile has variable effects as evident from previous reports [3]. In line 
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with this, the results of our study demonstrated no significant effect of Pb exposure 
(both at low and high dose) on the serum cholesterol levels of the rats during the 
experimental period and was comparable to the control. Further, the serum triglycer-
ide levels did not show either significant change in the groups exposed to low dose of 
Pb. Only the group exposed to the higher dose of lead (60 mg/kg) showed an elevat-
ed level of triglycerides and treatment with bromelain significantly reduced the levels 
in the serum. Similar to our results, no significant change in the serum cholesterol and 
triglycerides levels were reported in a study on long term exposure to Pb in albino 
rats [3]. Dyslipidemia is defined as elevated total cholesterol or triglycerides [23], 
thus the Pb-induced dyslipidemia observed at the higher dose of exposure was allevi-
ated by the bromelain treatment which could be attributed to its anti-inﬂammatory 
nature. Liver enzymes such as ALT and AST are marker enzymes for liver function 
and integrity [1]. These enzymes are usually elevated in acute hepatotoxicity or mild 
hepato-cellular injury, but also tend to decrease with prolonged intoxication due to 
liver damage [9]. In consensus with previous studies [15, 21], in the present study the 
serum ALT levels were increased by Pb exposure in a dose dependent manner in 
comparison to the control. And at both levels of lead exposure (30 mg/kg and 60 
mg/kg) the bromelain significantly reduced the serum ALT levels. Our findings are 
supported with the findings of a dose-response study by Bahde et al. [4] on the 
evaluation of immunomodulatory action of the protease bromelain for the treatment 
of hepatic ischemia/reperfusion (I/R) injury. It was reported that, after I/R, rats 
treated with 0.1 mg/kg b.w. bromelain showed an improved microcirculation, reduc-
tion in leukocyte adhesion, apoptosis rates, Kupffer cell activation and endothelial 
cell damage and significantly lower AST levels compared with untreated animals [4].
Based on a broad assessment of all the end points investigated in the present study 
bromelain proved to be effective in alleviating the lead-induced toxicity though the 
effect of bromelain was also not preferential over a particular dose of Pb. The use of 
natural antioxidants along or in conjunction with chelation therapy has not been 
extensively investigated yet. Bromelain known for its therapeutic potential is a 
widely used and recommended dietary supplement and its use could prove to be a 
potential novel strategy to treat pathological and toxicological consequences of oxi-
dative stress in conjugation with other antioxidants or chelators. Thus we recommend 
the potential use of bromelain as a phytotherapeutic agent in metal intoxication and a 
host of human diseases including metabolic disorders.
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